Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women's Health Initiative Randomized Controlled Trial

Journal of the American Medical Association

Volumn 291, Issue 14, 2004, Pages 1701-1712

  Anderson, Garnet L ^a   Limacher, Marian ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO; CONJUGATED ESTROGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONJUGATION; DRUG EFFECT; ESTROGEN ACTIVITY; ESTROGEN THERAPY; ETHNOLOGY; FEMALE; HAZARD ASSESSMENT; HIP FRACTURE; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MALIGNANT MENINGIOMA; MELANOMA; MENOPAUSAL SYNDROME; MENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RACE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; BREAST TUMOR; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COLORECTAL TUMOR; CORONARY ARTERY DISEASE; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODEL;

AGED; BREAST NEOPLASMS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COLORECTAL NEOPLASMS; CORONARY DISEASE; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HIP FRACTURES; HUMANS; HYSTERECTOMY; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; RISK ASSESSMENT;

EID: 1842867053     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.14.1701     Document Type: Article

References (45)

1. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
2. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation. 1987;75:1102-1109.
3. Grady D, Rueben SB, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
4. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991;151:67-72.
5. Steinberg KK, Thacker SB, Smith SJ, et al. A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997;350:1047-1059.
7. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
10. Hays J, Hunt JR, Hubbel A, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9 suppl):S18-S77.
11. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter]. JAMA. 1997;278:477.
12. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13:S5-S17.
13. Curb D, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(9 suppl):S122-S128.
14. Freedman LS, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Control Clin Trials. 1996;17:509-525.
15. Cox DR. Regression analysis and life tables. J R Stat Soc. 1972;34:187-220.
16. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-446.
17. NIH/NHLBI News Release. Statement from Barbara Alving, MD, Director of the Women's Health Initiative and Acting Director of the National Heart, Lung, and Blood Institute. Available at: http://www.nhlbi.nih.gov/new/press/O4-03-O2.htm. Accessed March 5, 2004.
18. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9 suppl):S78-S86.
19. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10.
20. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
21. Waters DD, Alderman EL, Has J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
22. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109:1056-1062.
23. ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002;360:2001-2008.
24. Hodis HN, Mack WJ, Azen SP, et al, for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545.
25. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
26. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
27. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
28. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
29. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
30. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
31. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.
32. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
33. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16.
34. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198.
35. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrinol Rev. 2002;23:529-539.
36. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-2897.
37. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. JAMA. 2002;288:872-881.
38. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243-3253.
39. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst. 2000;92:328-332.
40. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427.
41. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289:3254-3263.
42. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 1999;130:262-269.
43. Hsia J, Barad D, Margolis K, et al, for the Women's Health Initiative Research Group. Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (the Women's Health Initiative). Am J Cardiol. 2003;92:264-269.
44. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year following the initial prescription: a population-based study. Am J Obstet Gynecol. 2000;182:270-276.
45. FDA News Release. FDA updates hormone therapy information for postmenopausal women. February 10, 2004. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed March 5, 2004.